[go: up one dir, main page]

ZA200507552B - Medicament for the treatment of respiratory tract disorders - Google Patents

Medicament for the treatment of respiratory tract disorders Download PDF

Info

Publication number
ZA200507552B
ZA200507552B ZA200507552A ZA200507552A ZA200507552B ZA 200507552 B ZA200507552 B ZA 200507552B ZA 200507552 A ZA200507552 A ZA 200507552A ZA 200507552 A ZA200507552 A ZA 200507552A ZA 200507552 B ZA200507552 B ZA 200507552B
Authority
ZA
South Africa
Prior art keywords
medicament
plant material
respiratory tract
medicament according
tract disorders
Prior art date
Application number
ZA200507552A
Inventor
Austin M Phiri
Original Assignee
Austin M Phiri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Austin M Phiri filed Critical Austin M Phiri
Priority to ZA200507552A priority Critical patent/ZA200507552B/en
Publication of ZA200507552B publication Critical patent/ZA200507552B/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

2 200¢ 75/0755, :
MEDICAMENT FOR THE TREATMENT OF RESPIRATORY TRACT
DISORDERS
INTRODUCTION AND BACKGROUND TO THE INVENTION
This invention relates to a medicament for the treatment of respiratory tract disorders.
In this specification, the term ‘mammal’ includes within its scope, but is not limited to, humans.
Known compositions for the treatment of respiratory tract disorders usually contain chemical substances, many of which have a number of negative side effects to the user of the composition.
South African patent number ZA2003/8216 filed in the name of the applicant of this patent application, relates to a method and medicament for the treatment of immuno-deficiency conditions. The medicament comprises coal ash, grape seeds, pine bark extracts, a tincture of African potato (Hypoxis rooperi), calcium ascorbate and bioflavanoids. The medicament is effective in the treatment of immuno-deficiency conditions such as HIV/AIDS and cancer. The medicament improves and maintains the immune system of a user, reduces the frequency of opportunistic infections, accelerates healing and assists in the promotion of well-being.
The applicant has subsequently found that a medicament containing coal ash is an effective treatment for respiratory disorders when used together with certain plant material.
OBJECT OF THE INVENTION
It is therefore an object of the present invention to provide a medicament for the treatment of respiratory tract disorders, which is a useful alternative to known compositions.
SUMMARY OF THE INVENTION
According to a first aspect of the invention there is provided a medicament for the treatment of respiratory tract disorders comprising a pharmaceutically effective amount of coal ash and plant material or a derivative thereof obtained from plants of the species Vernonia glabra (phimatenous).
The medicament may include from 0.2% to 20%, preferably 0.59% coal ash on a mass per mass basis.
The plant material of the plants of the species Vernonia glabra (phimatenous) may be in the form of roots, stems, and leaves.
The medicament may include ash of the plant material.
The medicament may include from 0.2% to 20%, preferably 0.59% ash of the plant material on a mass per mass basis.
The medicament may include any one or more of the following: a preservative; a suitable carrier; and a sweetener.
The medicament may further include any one or more of the following: alcohol as the preservative; glycerine as the carrier; and sucrose as the sweetener.
The alcohol may be between 90% and 98% pure alcohol, preferably 94.4% pure alcohol.
The medicament may include from 4% to 20%, preferably 14.12% alcohol on a mass per mass basis; from 10% to 60%, preferably 42.35% glycerine on a mass per mass basis; and from 10% to 60%, preferably 42.35% sucrose on a mass per mass basis.
The medicament may be effective in the treatment of any one or more respiratory tract disorders selected from the group consisting of asthma; flu; croup; bronchitis; sore throat; and lung diseases.
According to a second aspect of the invention there is provided a pharmaceutically effective amount of coal ash and plant material or a derivative thereof obtained from plants of the species Vernonia glabra (phimatenous) for use in the treatment of respiratory tract disorders. 5
The respiratory tract disorders may be selected from the group consisting of asthma; flu; croup; bronchitis; sore throat; and lung diseases.
According to a third aspect of the invention there is provided use of a pharmaceutically effective amount of coal ash and plant material or a derivative thereof obtained from plants of the species Vernonia glabra (phimatenous) in the preparation of a medicament for the treatment of respiratory tract disorders.
The respiratory tract disorders may be selected from the group consisting of asthma; flu; croup; bronchitis; sore throat; and lung diseases.
The invention will now be described further by way of a non-limiting example.
EXAMPLE
According to a preferred embodiment of the invention, a medicament for the treatment of respiratory tract disorders comprises a pharmaceutically effective amount of coal ash and plant material or a derivative thereof obtained from plants of the species Vernonia glabra (phimatenous). The plant material is in the form of ash of the roots, stems, and leaves of the plant of the species
Vernonia glabra (phimatenous).
The medicament includes from 0.2% to 20% coal ash on a mass per mass basis and from 0.2% to 20% ash of the plant material on a mass per mass basis.
The medicament further includes a preservative in the form of alcohol; a suitable carrier in the form of glycerine; and a sweetener in the form of sucrose.
The alcohol is between 90% and 98% pure alcohol, preferably 94.4% pure alcohol. The medicament include from 4% to 20% alcohol on a mass per mass basis; from 10% to 60% glycerine on a mass per mass basis; and from 10% to 60% sucrose on a mass per mass basis.
A volume of 1 ml of the medicament comprises the following:
The Vernonia glabra (phimatenous) ash and coal ash are active ingredients, and the glycerine, sucrose, and alcohol are inactive ingredients.
The medicament is in the form of a syrup which is administered to a mammal in need thereof. From 2 ml to 10 ml of the medicament is administered to the mammal two to three times daily.
The applicant has found that the medicament is effective in the treatment of any one or more respiratory tract disorders selected from the group consisting of asthma; flu; croup; bronchitis; sore throat; and lung diseases.
It will be appreciated that variations in detail are possible with a medicament for the treatment of respiratory tract disorders according to the invention without departing from the scope of the appended claims.

Claims (21)

1. A medicament for the treatment of respiratory tract disorders comprising a pharmaceutically effective amount of coal ash and plant material or a derivative thereof obtained from plants of the species Vernonia glabra (phimatenous).
2. A medicament according to claim 1 which includes from 0.2% to 20% coal ash on a mass per mass basis.
3. A medicament according to claim 2 which includes 0.59% coal ash on a mass per mass basis.
4. A medicament according to any one of the preceding claims wherein the plant material of the plants of the species Vernonia glabra (phimatenous) are in the form of roots, stems, and leaves.
5. A medicament according to any one of the preceding claims which includes ash of the plant material.
6. A medicament according to claim 5 which includes from 0.2% to 20% ash of the plant material on a mass per mass basis.
7. A medicament according to claim 6 which includes 0.59% ash of the plant material on a mass per mass basis.
8. A medicament according to any one of the preceding claims which includes any one or more of the following: a preservative; a suitable carrier; and a sweetener.
9. A medicament according to claim 8 which further includes any one or more of the following: alcohol as the preservative; glycerine as the carrier; and sucrose as the sweetener.
10. A medicament according to claim 9 wherein the alcohol is between 90% and 98% pure alcohol.
11. A medicament according to claim 10 wherein the alcohol is 94.4% pure alcohol.
12. A medicament according to any one of claims 9 to 11 which includes from 4% to 20% alcohol on a mass per mass basis; from 10% to 60% glycerine on a mass per mass basis; and from 10% to 60% sucrose on a mass per mass basis.
13. A medicament according to claim 12 which includes 14.12% alcohol on a mass per mass basis; 42.35% glycerine on a mass per mass basis; and 42.35% sucrose on a mass per mass basis.
14. A medicament according to any one of the preceding claims which is effective in the treatment of any one or more respiratory tract disorders selected from the group consisting of asthma; flu; croup; bronchitis; sore throat; and lung diseases.
15. A pharmaceutically effective amount of coal ash and plant material or a derivative thereof obtained from plants of the species Vernonia glabra (phimatenous) for use in the treatment of respiratory tract disorders.
16. A pharmaceutically effective amount of coal ash and plant material or a derivative thereof obtained from plants of the species Vernonia glabra (phimatenous) according to claim 15 wherein the respiratory tract disorders are selected from the group consisting of asthma; flu; croup; bronchitis; sore throat; and lung diseases.
17.Use of a pharmaceutically effective amount of coal ash and plant material or a derivative thereof obtained from plants of the species Vernonia glabra (phimatenous) in the preparation of a medicament for the treatment of respiratory tract disorders.
18. Use according to claim 17 wherein the respiratory tract disorders are selected from the group consisting of asthma; flu; croup; bronchitis; sore throat; and lung diseases.
19.A medicament for the treatment of respiratory tract disorders substantially as herein described and exemplified.
20. A pharmaceutically effective amount of coal ash and plant material or a derivative thereof obtained from plants of the species Vernonia glabra (phimatenous) substantially as herein described and exemplified.
21.Use of a pharmaceutically effective amount of coal ash and plant material or a derivative thereof obtained from plants of the species Vernonia glabra (phimatenous) substantially as herein described and exemplified. “TH DATED THIS J... DAY OF SEPTEMBER 2005. I DM KISCH INC PATENT ATTORNEYS FOR THE APPLICANT
ZA200507552A 2004-09-10 2005-09-19 Medicament for the treatment of respiratory tract disorders ZA200507552B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ZA200507552A ZA200507552B (en) 2004-09-10 2005-09-19 Medicament for the treatment of respiratory tract disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200407288 2004-09-10
ZA200507552A ZA200507552B (en) 2004-09-10 2005-09-19 Medicament for the treatment of respiratory tract disorders

Publications (1)

Publication Number Publication Date
ZA200507552B true ZA200507552B (en) 2006-07-26

Family

ID=38181301

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200507552A ZA200507552B (en) 2004-09-10 2005-09-19 Medicament for the treatment of respiratory tract disorders

Country Status (1)

Country Link
ZA (1) ZA200507552B (en)

Similar Documents

Publication Publication Date Title
Sharma et al. Acorus calamus (The Healing Plant): A review on its medicinal potential, micropropagation and conservation
Lino et al. Analgesic and antiinflammatory activities of Justicia pectoralis Jacq and its main constituents: coumarin and umbelliferone
Rajvaidhya et al. A review on Acacia Arabica-an Indian medicinal plant
Gopukumar et al. Ficus benghalensis Linn–the sacred Indian medicinal tree with potent pharmacological remedies
Mali et al. Phcog Rev.: Plant review Rakta Kanchan (Bauhinia variegata): Chemistry traditional and medicinal uses—A review
Azeem et al. Fungi for human health
Toma et al. Phytochemical screening and toxicity studies of the aqueous extract of the pods pulp of Cassia sieberiana DC.(Cassia Kotchiyana Oliv.)
Deepthi et al. A comprehensive review of Sesbania grandiflora (L.) Pers: traditional uses, phytochemistry and pharmacological properties
Gopal et al. Investigation of in-vitro anti-oxidant, anti-inflammatory and anti-arthritic activity of aerial parts of Securinega leucopyrus (Willd.) Muell
Ezin et al. Azadirachta indica: Its biological, pharmacological, antidiabetic potential, and omics applications
Samuel et al. Echinacea purpurea-A potent medicinal herb.
Kang et al. The comparative study of immunomodulatory effect by Glycyrrhiza new varieties and official compendia
Mantena et al. Anti inflammatory activity of Erythrina Variegata
Kacemi et al. Bee Pollen as a Source of Pharmaceuticals: Where Are We Now?
ZA200507552B (en) Medicament for the treatment of respiratory tract disorders
RU2000116660A (en) BIOLOGICALLY ACTIVE FOOD ADDITIVE
GB9920886D0 (en) Herbal composition for treatment acene and fungal infection of skin and nails
Sikarwar et al. Cordia macleodii (Griff.) Hook. f. & Thomson (Boraginaceae)–A comprehensive review
Ugwu et al. Evaluation of the Antimicrobial Effects of Syzygium aromaticum (Clove) and Garcinia kola (Bitter kola) extracts singly and in Combination, on Some Bacteria
Prashar et al. A review on Myrica nagi approach in recognizing the overall potential of the plant
Mali et al. Bauhinia variegata Linn.(Mountain Ebony): A review on ethnobotany, phytochemistry and pharmacology
Narayanan et al. Coastal sand dune plants as a valuable resource of bioactive metabolites in pharmaceutical field
Nazreen Ethnomedicinal uses, Pharmacological and phytochemical studies of bambusa arundinaceae retz (a review)
Kikowska et al. Biotechnological stimulation of phenolics in Lychnis flos-cuculi shoot cultures
Udvardy et al. A perspective on the anti-infective activity of Goldenseal (Hydrastis Canadensis) and its contribution to the development of multidrug pump inhibitors